
Vibcare Pharma
09/10/26
| Brand | Company | Common pack and MRP (Rs) – Tata 1mg, read 9 Oct 2026 |
|---|---|---|
| Taxim-O 200 Tablet | Alkem Laboratories Ltd | Strip of 10, ₹105.1 |
| Zifi 200 Tablet | FDC Limited | Strip of 10, ₹105.11 |
| Cefolac 200 Tablet | Macleods Pharmaceuticals Pvt Ltd | Strip of 10, ₹105.09 |
| cEFix 200 Tablet | Cipla Ltd | Strip of 10, ₹104.46 |
| Omnix 200 DT Tablet (dispersible) | Cipla Ltd | Strip of 10, ₹104.47 |
| Ceftas 200 Tablet | Intas Pharmaceuticals Ltd | Strip of 10, ₹99.93 |
| Mahacef 200 Tablet | Mankind Pharma Ltd | Strip of 10, ₹99.76 |
| Milixim 200 Tablet | Glenmark Pharmaceuticals Ltd | Strip of 10 |
| Zifi 100 Dry Syrup | FDC Limited | 30 mL bottle, ₹77.05 |
| Taxim-O Forte Dry Syrup | Alkem Laboratories Ltd | 30 mL bottle, ₹77.02 |
| Cefolac 100 Oral Suspension | Macleods | 30 mL bottle, ₹77 |
| Omnix 100 Dry Syrup | Cipla Ltd | 30 mL bottle, ₹76.54 |
| Mahacef 100 Dry Syrup | Mankind Pharma Ltd | 30 mL bottle, ₹74.95 |
| Taxim OF Tablet (cefixime 200 mg + ofloxacin 200 mg) | Alkem Laboratories Ltd | Strip of 10, ₹217.55 |
| Zifi O 200mg/200mg Tablet | FDC Ltd | Strip of 10, ₹208.3 |
| Cefolac-O 200 Tablet (cefixime 200 mg + ofloxacin 200 mg) | Macleods | Strip of 10, ₹217.7 |
| Ceftas O Tablet (cefixime 200 mg + ofloxacin 200 mg) | Intas Pharmaceuticals Ltd | Strip of 10, ₹216.56 |
| Omnix O Tablet (cefixime 200 mg + ofloxacin 200 mg) | Cipla Ltd | Strip of 10, ₹219.2 |
| Mahacef-Plus Tablet (cefixime 200 mg + ofloxacin 200 mg) | Mankind Pharma Ltd | Strip of 10, ₹173.42 |
| Taxim-O CV 200 Tablet (cefixime 200 mg + clavulanic acid 125 mg) | Alkem | Strip of 10, ₹278.4 |
| Zifi CV 200 Tablet (cefixime 200 mg + clavulanic acid 125 mg) | FDC Ltd | Strip of 10, ₹364.34 |
| Omnix CV Tablet (cefixime 200 mg + clavulanic acid 125 mg) | Cipla | Strip of 10, ₹347.9 |
| Ceftas CV 200 mg/125 mg Tablet | Intas | Strip of 10, ₹358.13 |
| Mahacef-CV 200 Tablet (cefixime 200 mg + clavulanic acid 125 mg) | Mankind | Strip of 6, ₹185.55 |
| Cefolac CV 200 Tablet (cefixime 200 mg + clavulanic acid 125 mg) | Macleods | Strip of 4, ₹153.1 |
| Ziprax LB Tablet DT (cefixime 200 mg + lactic acid bacillus 60 million spores) | Cipla Ltd | Strip of 10, ₹91.45 |
| Cefitaxe 200 DT Tablet (cefixime 200 mg + lactic acid bacillus 60 million spores) | Leeford Healthcare Ltd | Strip of 10, ₹104 |
Every MRP above is the printed MRP shown on the Tata 1mg product page read on 9 October 2026, inclusive of taxes, except Milixim 200, whose product page showed no MRP line. MRPs vary by batch and change over time, so please check the current price at a pharmacy.
Cefixime is an oral third-generation cephalosporin antibiotic, a class of medicine within the wider beta-lactam family that also includes penicillins. The UK summary of product characteristics describes it under ATC code J01DD08, and the US label calls it a semisynthetic cephalosporin antibacterial for oral administration.
Cefixime kills bacteria rather than simply slowing them down. The US label states that the bactericidal action of cefixime results from inhibition of cell wall synthesis, so in plain words the bacteria cannot hold together.
It is described as stable in the presence of certain beta-lactamase enzymes, the enzymes some bacteria use to resist penicillins, so some of those bacteria may still be susceptible to cefixime. The same label lists organisms that are resistant to it, including Pseudomonas, Enterococcus, most staphylococci and most Enterobacter, and notes limited activity against bacteria producing extended-spectrum beta-lactamases.
NLEM 2022 lists cefixime as tablet 200 mg, tablet 400 mg, oral liquid 50 mg/5 mL and oral liquid 100 mg/5 mL. Indian pharmacy catalogues additionally list 100 mg tablets, dispersible tablets of 50 mg, 100 mg and 200 mg, dry syrups of 50 mg, 100 mg and 200 mg per 5 mL in 30 mL and 60 mL bottles, and paediatric drops.
Around 40% to 50% of an oral dose of cefixime is absorbed, and the serum half-life in healthy subjects averages 3 to 4 hours. The WHO Model List of Essential Medicines lists cefixime as powder for oral liquid 100 mg/5 mL and as solid oral dosage forms of 200 mg and 400 mg.
Cefixime is used only for infections proven or strongly suspected to be caused by susceptible bacteria, and the approved uses differ slightly between the US, the UK and Indian sources.
The US label for cefixime oral suspension and 400 mg capsule lists uncomplicated urinary tract infections caused by susceptible Escherichia coli and Proteus mirabilis; otitis media caused by susceptible Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes; pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes; acute exacerbations of chronic bronchitis caused by susceptible Streptococcus pneumoniae and Haemophilus influenzae; and uncomplicated cervical or urethral gonorrhoea caused by susceptible Neisseria gonorrhoeae. The US 400 mg tablet label limits the urinary tract, bronchitis and gonorrhoea uses to patients weighing more than 45 kg or older than 12 years.
The UK summary of product characteristics lists acute infections caused by susceptible organisms: upper respiratory tract infections such as otitis media where the organism is known or suspected to be resistant to other commonly used antibiotics or where treatment failure carries significant risk, lower respiratory tract infection such as bronchitis, and urinary tract infections such as cystitis, cystourethritis and uncomplicated pyelonephritis.
The ICMR 2019 treatment guidelines list cefixime as an alternative, not a first choice, for typhoid fever, and name cefixime in a few specific situations, such as in children with non-anaphylactic penicillin allergy in bacterial sinusitis, and within a regimen for mild-to-moderate pelvic inflammatory disease. Typhoid fever is not an indication in the US label, and a 2022 Cochrane review concluded that cefixime can be used for enteric fever but may not perform as well as fluoroquinolones, while a 2026 trial of 1,847 patients found no benefit from adding cefixime to azithromycin.
CDSCO's approved-combination records give the indication for cefixime with ofloxacin as "typhoid fever and urinary tract infection in adults", and for cefixime with lactic acid bacillus as "urinary tract infections, respiratory tract infections, biliary tract infections in adult patients prone to antibiotic associated diarrhoea". For cefixime with clavulanic acid the CDSCO list shows only the word "Antibiotic" in the indication column.
Cefixime does not treat viral infections such as the common cold. The US label states that antibacterial drugs, including cefixime, should only be used to treat bacterial infections, and the ICMR guidelines state that antimicrobial therapy is not indicated for viral upper respiratory infections and that antibiotics are not indicated for acute bronchitis.
The doses below are the doses written in the official labels and guidelines, not advice for any individual; always take cefixime in the exact dose and for the exact duration your doctor prescribes.
The usual adult dose stated in the US label is 400 mg daily, either as one 400 mg tablet daily or as half a 400 mg tablet every 12 hours. For uncomplicated cervical or urethral gonorrhoea the label states a single oral dose of 400 mg, and in Streptococcus pyogenes infections treatment is stated as at least 10 days.
The UK summary of product characteristics states 200 to 400 mg daily for adults and children over 10 years or weighing more than 50 kg, given either as a single dose or in two divided doses according to the severity of infection, with a usual course of 7 days, which may be continued for up to 14 days if required.
The US label, for children 6 months and older on the oral suspension, states 8 mg/kg/day given as one daily dose or in two divided doses of 4 mg/kg every 12 hours, and its weight chart runs from 50 mg daily for a 5 to 7.5 kg child up to 400 mg daily for 45.1 kg or more. Children weighing more than 45 kg or older than 12 years are treated with the recommended adult dose, and safety under 6 months of age is not established. For otitis media the label states the suspension should be used and that the tablet or capsule should not be substituted for it.
The ICMR 2019 standard-dose table lists cefixime as 20 mg/kg/day, and for typhoid gives a duration of 10 to 14 days. The UK 200 mg tablet is not recommended for children under 10 years.
Both the US and UK labels state that cefixime can be taken without regard to food or meals; the US label notes that food delays the time to peak and lowers absorption of the 400 mg capsule to some extent. In kidney impairment the dose may need to change, and the labels differ by country and by form: the US label keeps the normal dose only if creatinine clearance is 60 mL/min or more, says the 400 mg tablet is not appropriate between 21 and 59 mL/min or on haemodialysis, and gives separate reduced doses for the suspension, while the UK label keeps the normal dose down to 20 mL/min and caps it at 200 mg once daily below that. The doctor sets the dose from kidney function; do not change it yourself.
A reconstituted bottle of the US-label suspension may be kept for 14 days at room temperature or in a refrigerator, shaken well before each use, and any leftover portion discarded after 14 days. For the cefixime combinations with ofloxacin, lactic acid bacillus or clavulanic acid, no official combination dose was found in the CDSCO, US or UK sources used, so the dose must be taken only as prescribed by the doctor from the product's own verified prescribing information.
The most common side effects of cefixime are stomach and bowel related, and most reactions are described as mild and self-limiting.
In US trials of the tablet, gastrointestinal events were reported in 30% of adult patients, and 5% of patients stopped treatment because of drug-related adverse reactions. The individual rates listed are diarrhoea 16%, nausea 7%, loose or frequent stools 6%, flatulence 4%, abdominal pain 3% and dyspepsia 3%, with vomiting also listed; in children on the suspension, gastrointestinal effects were comparable to those in adults.
The UK summary adds headache, dizziness, rash, itching and urticaria without giving frequencies, and notes that diarrhoea has been more commonly associated with higher doses and that treatment should be stopped if marked diarrhoea occurs.
Wherever cefixime is combined with ofloxacin, in tablets or in dry syrups, the ofloxacin label carries a boxed warning about disabling and potentially irreversible reactions that can occur together, such as tendinitis and tendon rupture, peripheral neuropathy and central nervous system effects; the label says to stop the medicine at once if any of these occur. The same warning says ofloxacin may worsen muscle weakness in myasthenia gravis and should be avoided in people with a known history of it. The tendon risk is higher above 60 years of age, with corticosteroids, and after kidney, heart or lung transplant, and tendon rupture can occur up to several months after the course ends.
Cefixime must not be taken by anyone with a known allergy to cefixime or to other cephalosporins, and it must be used with caution in people with a history of penicillin allergy. Cefixime + ofloxacin products must also not be taken by anyone with a history of allergy to ofloxacin or any other quinolone antibiotic.
The US label states that published data over several decades have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes, while the UK summary states that Suprax should not be used in pregnancy or in nursing mothers unless considered essential by the physician. For breastfeeding, the US label reports no data on the presence of cefixime in human milk and advises weighing the benefits of breastfeeding against the mother's need for the medicine.
For the ofloxacin-containing combination, the ofloxacin label states that safety and efficacy in patients under 18 years, pregnant women and lactating women have not been established. The label also advises not to take antacids containing calcium, magnesium or aluminium, sucralfate, iron, zinc-containing supplements or mineral supplements within two hours before or two hours after ofloxacin, because they reduce its absorption.
Cefixime is a Schedule H1 antibiotic in India, which means it can be sold only against the prescription of a Registered Medical Practitioner and every sale is recorded.
Cefixime is named in Schedule H1 of the Drugs and Cosmetics Rules, 1945, and the rules require the formulation to carry a red "Rx" symbol at the top left and a box with a red border reading "SCHEDULE H1 DRUG - WARNING. It is dangerous to take this preparation except in accordance with the medical advice. Not to be sold by retail without the prescription of a Registered Medical Practitioner." Supply of a Schedule H1 drug is entered in a separate register, with records kept for three years and open to inspection.
The Ministry of Health's Red Line awareness campaign on antimicrobial resistance urges people not to use medicines marked with a red vertical line without a doctor's prescription, and antibiotics are included among the medicines covered by the campaign.
NLEM 2022 lists cefixime at item 6.2.1.8 under beta-lactam medicines, with tablet 200 mg, tablet 400 mg and oral liquids of 50 mg/5 mL and 100 mg/5 mL. The list does not include cefixime combined with ofloxacin, lactic acid bacillus or clavulanic acid, and clavulanic acid appears there only with amoxicillin.
One price is quoted here because it is dated and sourced: the ceiling price of cefixime capsule 400 mg is ₹37.28 per capsule with effect from 1 April 2026, as part of the annual wholesale price index revision; the source is a news reproduction of the NPPA notification table rather than the NPPA document itself. Because the combinations are not in NLEM 2022, no NLEM-based ceiling price for them was found.
The WHO AWaRe classification places cefixime in the WATCH group of third-generation cephalosporins, a group the WHO says has higher resistance potential and should be a key target of stewardship programmes and monitoring. On the WHO Model List of Essential Medicines 2025, cefixime has no first-choice indication and second-choice indications for acute invasive bacterial diarrhoea or dysentery and for gonorrhoea.
Cefixime is sold in India by many companies in tablets, dispersible tablets, dry syrups and the common combinations with ofloxacin, clavulanic acid and lactic acid bacillus; the table at the top of this page lists widely available brands, their companies, packs and the MRP printed on Tata 1mg on 9 October 2026. No published sales ranking from a named data source was found, so this is a list of widely available brands and not a ranking of bestsellers.
Vibcare's cefixime range covers 32 products in 9 compositions: single-ingredient tablets and dispersible tablets of 100 mg and 200 mg, dry syrups of 50 mg and 100 mg, and fixed combinations with ofloxacin, with lactic acid bacillus 60 million spores and with clavulanic acid 125 mg, in packs from 30 mL bottles to 10x10 alu-alu packs.
4 divisions
4 divisions
2 divisions
4 divisions
4 divisions
Prima
2 divisions
Prima
3 divisions
Add cefixime to your range
Vibcare appoints one PCD franchise partner per district, with monopoly rights confirmed in writing. Trade rates for every product are on its product page.
In India, the ICMR 2019 guidelines list cefixime as an alternative drug for typhoid fever, to be given for 10 to 14 days and changed as per susceptibility testing, while CDSCO has approved a cefixime and ofloxacin combination for typhoid fever and urinary tract infection in adults. Typhoid fever is not an indication in the US label, a 2022 Cochrane review says cefixime may not perform as well as fluoroquinolones for enteric fever, and a 2026 trial found no benefit from adding cefixime to azithromycin.
Both the US and the UK labels state that cefixime can be taken without regard to food or meals, and the UK label says absorption is not significantly modified by food. Neither label mentions milk specifically, so for a milk-related doubt please ask your doctor or pharmacist.
The US label supports use of the oral suspension from 6 months of age at the dose stated in the label, and says safety and effectiveness under 6 months of age are not established; the UK 200 mg tablet is not recommended for children under 10 years. Children must be given cefixime only in the dose a doctor prescribes, and for otitis media the label states the suspension should be used instead of the tablet or capsule.
No. Cefixime is an antibacterial medicine and does not treat viral infections such as the common cold; the US label states that antibacterial drugs, including cefixime, should only be used to treat bacterial infections. The ICMR guidelines state that antimicrobial therapy is not indicated for viral upper respiratory infections and that antibiotics are not indicated for acute bronchitis.
The US label says that it is common to feel better early in the course, but the medicine should be taken exactly as directed by the doctor, because skipping doses or not finishing the course may reduce effectiveness and increase resistance. Do not stop or change the course on your own; speak to your prescribing doctor.
The US label states that published human data have not established drug-associated risks of major birth defects, miscarriage or adverse maternal and fetal outcomes, while the UK summary says cefixime should not be used in pregnancy or by nursing mothers unless the physician considers it essential. There are no human milk data in the US label, so any decision in pregnancy or breastfeeding must be taken by the treating doctor.
Diarrhoea was the most common side effect in the US trials at 16%, with loose or frequent stools at 6%, and the UK label says diarrhoea is more common at higher doses. Watery or bloody stools, with or without cramps and fever, need to be reported to a doctor even more than two months after the last dose, because Clostridioides difficile-associated diarrhoea has been reported to occur over two months after antibacterial treatment.
A Cochrane review in children found diarrhoea in 8% of those given probiotics compared with 19% of controls, described as moderate-certainty evidence, though the review covered mixed probiotic strains and not this specific combination. A 2025 Cochrane update in adults and children found that probiotics may reduce Clostridioides difficile-associated diarrhoea on low-certainty evidence.
Cefixime is named in Schedule H1 of the Drugs and Cosmetics Rules, 1945, and the rules state that it is dangerous to take the preparation except in accordance with medical advice and that it is not to be sold by retail without the prescription of a Registered Medical Practitioner. Each supply of a Schedule H1 drug is recorded in a separate register, with records kept for three years and open to inspection.
Add cefixime to your range
Vibcare appoints one PCD franchise partner per district, with monopoly rights confirmed in writing. Trade rates for every product are on its product page.
Copy Link